title: Salidroside alleviates oxidative stress in the liver with non- alcoholic steatohepatitis in rats.
abstract: BACKGROUND
  Nonalcoholic steatohepatitis (NASH) is characterized by fat accumulation in the hepatocyte, inflammation, liver cell injury, and varying degrees of fibrosis, and can lead to oxidative stress in liver. Here, we investigated whether Salidroside, a natural phenolic antioxidant product, can protect rat from liver injury during NASH.
  
  
  METHODS
  NASH model was established by feeding the male SD rats with high-fat and high-cholesterol diet for 14 weeks. Four groups of male SD rats including, normal diet control group, NASH model group, and Salidroside treatment group with150mg/kg and 300 mg/kg respectively, were studied. Salidroside was given by oral administration to NASH in rats from 9 weeks to 14 weeks. At the end of 14 weeks, liver and serum were harvested, and the liver injury, oxidative stress and histological features were evaluated.
  
  
  RESULTS
  NASH rats exhibited significant increases in the following parameters as compared to normal diet control rats: fat droplets with foci of inflammatory cell infiltration in the liver. ALT, AST in serum and TG, TC in hepatocyte elevated. Oxidative responsive genes including CYP2E1 and Nox2 increased. Additionally, NASH model decreased antioxidant enzymes SOD, GSH, GPX, and CAT in the liver due to their rapid depletion after battling against oxidative stress. Compared to NASH model group, treatment rats with Salidroside effectively reduced lipid accumulation, inhibited liver injury in a does-dependent manner. Salidroside treatment restored antioxidant enzyme levels, inhibited expression of CYP2E1 and Nox2 mRNA in liver, which prevented the initial step of generating free radicals from NASH.
  
  
  CONCLUSIONS
  The data presented here show that oral administration of Salidroside prevented liver injury in the NASH model, likely through exerting antioxidant actions to suppress oxidative stress and the free radical-generating CYP2E1 enzyme, Nox2 in liver.
authors.affiliation: Department of Gastroenterology, the first Affiliated Hospital of Dalian Medical University, 222, Zhongshan Road, Dalian, 116011, Liaoning Province, China.
authors.forename: Ze-ran
authors.initials: ZR
authors.lastname: Yang
authors.affiliation: Department of Gastroenterology, the first Affiliated Hospital of Dalian Medical University, 222, Zhongshan Road, Dalian, 116011, Liaoning Province, China.
authors.forename: Hui-fang
authors.initials: HF
authors.lastname: Wang
authors.affiliation: Department of Gastroenterology, the first Affiliated Hospital of Dalian Medical University, 222, Zhongshan Road, Dalian, 116011, Liaoning Province, China.
authors.forename: Tie-cheng
authors.initials: TC
authors.lastname: Zuo
authors.affiliation: Department of Digestive Physiology, Dalian Medical University, Dalian, Liaoning Province, China.
authors.forename: Li-li
authors.initials: LL
authors.lastname: Guan
authors.affiliation: Department of Gastroenterology, the first Affiliated Hospital of Dalian Medical University, 222, Zhongshan Road, Dalian, 116011, Liaoning Province, China. dainingdn@live.com.
authors.forename: Ning
authors.initials: N
authors.lastname: Dai
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D019392:Cytochrome P-450 CYP2E1 / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D059305:Diet, High-Fat / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004794:Enzyme Repression / Q000187:drug effects; D005960:Glucosides / Q000008:administration & dosage / Q000627:therapeutic use*; D066292:Lipid Droplets / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D050356:Lipid Metabolism / Q000187:drug effects; D015227:Lipid Peroxidation / Q000187:drug effects; D008099:Liver / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008297:Male; D008562:Membrane Glycoproteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D000074662:NADPH Oxidase 2; D019255:NADPH Oxidases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D065626:Non-alcoholic Fatty Liver Disease / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D018384:Oxidative Stress / Q000187:drug effects*; D010088:Oxidoreductases / Q000737:chemistry / Q000378:metabolism; D010636:Phenols / Q000008:administration & dosage / Q000627:therapeutic use*; D011897:Random Allocation; D017207:Rats, Sprague-Dawley; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D000975:Antioxidants; D005960:Glucosides; D008562:Membrane Glycoproteins; D010636:Phenols; D010088:Oxidoreductases; D019392:Cytochrome P-450 CYP2E1; C500593:Cybb protein, rat; D000074662:NADPH Oxidase 2; D019255:NADPH Oxidases; C009172:rhodioloside
keywords: CYP2E1; Non-alcoholic steatohepatitis; Nox2; Oxidative stress; Salidroside